Saturday, December 13, 2025 | 01:54 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Lupin gets approval to market Bimatroprost Ophthalmic Solution, 0.03%

Image

Capital Market

From USFDA

Lupin announced that it has received final approval for its Bimatroprost Ophthalmic Solution, 0.03% from the United States Food & Drug Administration (FDA) to market a generic version of Allergen Inc.'s Lumigan Ophthalmic Solution 0.03%.

Powered by Capital Market - Live News

 

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 23 2015 | 1:50 PM IST

Explore News